EDAP Presents Ablatherm-HIFU Data in Localized Prostate Cancer at Third Focal Therapy Symposium
2010年3月5日 - 6:32PM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, reported today its successful participation at the
Third International Workshop on Focal Therapy and Imaging of
Prostate and Kidney Cancer, held February 24-27, 2010 in
Washington, D.C. During the high-level workshop, EDAP organized a
specific Symposium, included in the official program, dedicated to
Ablatherm-HIFU focal therapy for localized prostate cancer.
Pr. Christian Chaussy, from Munich, Germany, with more than 15
years of experience with Ablatherm-HIFU, moderated sessions and
presented the growing interest and perspectives on the use of focal
therapy for prostate cancer in Europe. Pr. Roland Van Velthoven,
from Institut Bordet, Belgium, and Dr. Sebastien Crouzet, from
Edouard Herriot Hospital, Lyon, France, presented promising results
on focal Ablatherm-HIFU in the primary treatment of localized
cancer and salvage radiotherapy.
The presentations reflected the broadening use of Ablatherm-HIFU
in focal therapy in Europe and EDAP's position at the forefront of
focal therapy by offering patients a controlled minimally invasive
solution to prostate cancer. In the past 10 years, more than 21,000
Ablatherm-HIFU treatments have been performed worldwide. Based on
their strong experience, expert physicians in Europe are now keen
to adopt a more focal approach to the disease offering patients the
ability to fully control their early stage prostate cancer, while
minimizing side effects and improving their quality of life.
Among the growing number of prostate cancers diagnosed every
year, the majority are being detected during the early, low-risk
disease stage. Focal therapy will become the most adapted minimally
invasive alternative to more invasive surgery and radiotherapy
treatments for low risk cancers as it offers a dedicated solution
before the disease progresses and requires more radical
intervention.
The focal approach to prostate cancer disease is analogous to
targeted breast cancer therapy which specifically treats the tumor,
without requiring breast removal, to deliver positive benefits to
patients at a lower cost of treatment.
Marc Oczachowski, EDAP's Chief Executive Officer, commented,
"Feedback from the Third International Workshop on Focal Therapy
demonstrated the high level of interest and excitement surrounding
HIFU as a focal approach to localized prostate cancer. In an era
where we have the technologies to frequently detect early-stage,
low-grade prostate cancer, a minimally invasive treatment such as
focal Ablatherm-HIFU will play an increasing role in ablating a
targeted tumor and in controlling the disease while reducing risks
for incontinence and impotence."
Marc Oczachowski continued, "We are enthusiastic about the
growing number of Ablatherm-HIFU sites adopting focal approach in
Europe for the treatment of prostate cancer. Confirming the high
level of interest, a clinical study was initiated in September 2009
by AFU (French Association of Urology) and includes 10 clinical
centers to validate the effectiveness of Ablatherm-HIFU focal
therapy and demonstrate the significant patient benefits."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com and http://www.pcaresearch.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. These include statements regarding the company's
growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ
materially from those described in these forward-looking
statements. Factors that may cause such a difference include, but
are not limited to, those described in the company's filings with
the Securities and Exchange Commission. Ablatherm-HIFU treatment is
in clinical trials, but not FDA-approved or marketed in the United
States.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 6 2024 まで 7 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 7 2023 まで 7 2024